- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06318065
Surgical Resection Outcomes in Patients With Brain Metastasis
March 20, 2024 updated by: National Cheng-Kung University Hospital
Prognostic Factors Impacting Surgical Resection Outcomes in Patients With Brain
While many studies have investigated the prognostic factors for patients undergoing surgical resection for primary brain tumors, decision-making for patients with brain metastasis (BM) is more complex because of their higher burden of comorbidities compared to those with primary brain tumors.
In addition, although various prognostic indicators have been identified to predict prognosis in several types of cancer, such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), and systemic immune-inflammation index (SII), limited studies have yet determined which group of patients would yield beater survival outcome after surgical resection for BM.
This study aimed to investigate the impact of patient and perioperative characteristics and prognostic indicators on survival outcome of patients undergoing surgical resection of BM.
Study Overview
Status
Recruiting
Conditions
Study Type
Observational
Enrollment (Estimated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jung-Shun Lee, M.D.
- Phone Number: 5181 886-6-2353535
- Email: nslee1218@gmail.com
Study Locations
-
-
None Selected
-
Tainan, None Selected, Taiwan, 70403
- Recruiting
- Jung-Shun Lee
-
Contact:
- Jung-Shun Lee, M.D.
- Phone Number: 5181 886-6-2353535
- Email: nslee1218@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients newly diagnosed with BM due to various primary cancers who underwent surgery at our institution
Description
Inclusion Criteria:
- patients with Clinical diagnosis of brain metastasis
- patients who underwent craniotomy surgery for brain metastasis
Exclusion Criteria:
- patients with insufficient data for associated factors
- patients who underwent stereotactic biopsy for brain metastasis
- patients who did not undergo craniotomy surgery for brain metastasis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
survival outcome of patients undergoing surgery for brain metastasis
Time Frame: From date of surgery until the date of death from any cause, whichever came first, assessed up to 100 months
|
overall survival of patients
|
From date of surgery until the date of death from any cause, whichever came first, assessed up to 100 months
|
|
Functional outcome of patients undergoing surgery for brain metastasis
Time Frame: from date of surgery until 6 months after surgery ordate of death from any cause, whichever came first
|
change of preoperative and postoperative modified rankin scale
|
from date of surgery until 6 months after surgery ordate of death from any cause, whichever came first
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Jung-Shun Lee, M.D., National Cheng Kung Univsersity Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2010
Primary Completion (Estimated)
June 1, 2024
Study Completion (Estimated)
September 1, 2024
Study Registration Dates
First Submitted
February 25, 2024
First Submitted That Met QC Criteria
March 18, 2024
First Posted (Actual)
March 19, 2024
Study Record Updates
Last Update Posted (Actual)
March 22, 2024
Last Update Submitted That Met QC Criteria
March 20, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B-ER111-370
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.